» Articles » PMID: 25538088

Spectrin Repeat Containing Nuclear Envelope 1 and Forkhead Box Protein E1 Are Promising Markers for the Detection of Colorectal Cancer in Blood

Abstract

Identifying biomarkers in body fluids may improve the noninvasive detection of colorectal cancer. Previously, we identified N-Myc downstream-regulated gene 4 (NDRG4) and GATA binding protein 5 (GATA5) methylation as promising biomarkers for colorectal cancer in stool DNA. Here, we examined the utility of NDRG4, GATA5, and two additional markers [Forkhead box protein E1 (FOXE1) and spectrin repeat containing nuclear envelope 1 (SYNE1)] promoter methylation as biomarkers in plasma DNA. Quantitative methylation-specific PCR was performed on plasma DNA from 220 patients with colorectal cancer and 684 noncancer controls, divided in a training set and a test set. Receiver operating characteristic analysis was performed to measure the area under the curve of GATA5, NDRG4, SYNE1, and FOXE1 methylation. Functional assays were performed in SYNE1 and FOXE1 stably transfected cell lines. The sensitivity of NDRG4, GATA5, FOXE1, and SYNE1 methylation in all stages of colorectal cancer (154 cases, 444 controls) was 27% [95% confidence interval (CI), 20%-34%), 18% (95% CI, 12%-24%), 46% (95% CI, 38%-54%), and 47% (95% CI, 39%-55%), with a specificity of 95% (95% CI, 93%-97%), 99% (95% CI, 98%-100%), 93% (95% CI, 91%-95%), and 96% (95% CI, 94%-98%), respectively. Combining SYNE1 and FOXE1, increased the sensitivity to 56% (95% CI, 48%-64%), while the specificity decreased to 90% (95% CI, 87%-93%) in the training set and to 58% sensitivity (95% CI, 46%-70%) and 91% specificity (95% CI, 80%-100%) in a test set (66 cases, 240 controls). SYNE1 overexpression showed no major differences in cell proliferation, migration, and invasion compared with controls. Overexpression of FOXE1 significantly decreased the number of colonies in SW480 and HCT116 cell lines. Overall, our data suggest that SYNE1 and FOXE1 are promising markers for colorectal cancer detection.

Citing Articles

Reduced expression of in differentiated thyroid cancer, the contribution of CPG methylation, and their clinical relevance.

De Lima E, Dos Santos F, Da Silva I, De Lima C, Frutuoso V, Caso G Front Endocrinol (Lausanne). 2024; 15:1454349.

PMID: 39588344 PMC: 11586194. DOI: 10.3389/fendo.2024.1454349.


Advances in blood DNA methylation-based assay for colorectal cancer early detection: a systematic updated review.

Khabbazpour M, Tat M, Karbasi A, Abyazi M, Khodadoustan G, Heidary Z Gastroenterol Hepatol Bed Bench. 2024; 17(3):225-240.

PMID: 39308542 PMC: 11413380. DOI: 10.22037/ghfbb.v17i3.2978.


Forkhead box E1, frequently downregulted by promoter methylation, inhibits colorectal cancer cell growth and migration.

Shi Q, Huang Z, Kuang Y, Wang C, Fang X, Hu X Cancer Cell Int. 2024; 24(1):169.

PMID: 38734646 PMC: 11088116. DOI: 10.1186/s12935-024-03352-y.


The Effect of LL37 Antimicrobial Peptide on FOXE1 and lncRNA PTCSC 2 Genes Expression in Colorectal Cancer (CRC) and Normal Cells.

Al-Darraji M, Jasim S, Salah Aldeen O, Ghasemian A, Rasheed M Asian Pac J Cancer Prev. 2022; 23(10):3437-3442.

PMID: 36308369 PMC: 9924353. DOI: 10.31557/APJCP.2022.23.10.3437.


The Interaction Between Epigenetic Changes, EMT, and Exosomes in Predicting Metastasis of Colorectal Cancers (CRC).

Yang M, Sun M, Zhang H Front Oncol. 2022; 12:879848.

PMID: 35712512 PMC: 9197117. DOI: 10.3389/fonc.2022.879848.


References
1.
Akiyama Y, Watkins N, Suzuki H, Jair K, van Engeland M, Esteller M . GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol. 2003; 23(23):8429-39. PMC: 262684. DOI: 10.1128/MCB.23.23.8429-8439.2003. View

2.
Oh T, Kim N, Moon Y, Kim M, Hoehn B, Park C . Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. J Mol Diagn. 2013; 15(4):498-507. DOI: 10.1016/j.jmoldx.2013.03.004. View

3.
Muller H, Oberwalder M, Fiegl H, Morandell M, Goebel G, Zitt M . Methylation changes in faecal DNA: a marker for colorectal cancer screening?. Lancet. 2004; 363(9417):1283-5. DOI: 10.1016/S0140-6736(04)16002-9. View

4.
Muller H, Millinger S, Fiegl H, Goebel G, Ivarsson L, Widschwendter A . Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool. Clin Chem. 2004; 50(11):2171-3. DOI: 10.1373/clinchem.2004.034090. View

5.
Mandel J, Bond J, Church T, Snover D, Bradley G, SCHUMAN L . Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993; 328(19):1365-71. DOI: 10.1056/NEJM199305133281901. View